The Dementia Diagnosis Gap Is Wider Than We Think
Alzheimer’s costs American families upwards of $360 billion per year, and with our growing aging population, the disease needs to be more of a public health priority.
Why Blood is Best: Transforming the Diagnostic Journey for Alzheimer’s Disease
As the pool of approved therapies continues to (hopefully) expand, the clinical and diagnostic testing communities need to do a better job at ensuring the right patients move through this journey more quickly – and accurately – to improve their health and prognosis.
presented by
Navina’s AI Copilot Eases the Value-Based Burden, Study Shows
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
Transforming Our Collective Approach to Alzheimer’s Disease Care Begins with Early and Accurate Diagnosis
While advancements in diagnostics are promising, the need remains for healthcare professionals to take the lead on proactive conversations with patients and their loved ones about the early signs and symptoms of Alzheimer’s disease.
Why We Urgently Need More Widely Available Tests for Alzheimer’s Disease
Early diagnosis through blood tests buys invaluable time – for patients and their families to plan, seek support, make informed decisions about their difficult care journey and, perhaps most importantly, be together.
NeuroTrack, maker of a super-early Alzheimer’s diagnostic, raises $1M
By the time Alzheimer’s disease is diagnosed in most patients, extensive brain damage has already occurred. Palo Alto startup Neurotrack Technologies is developing a predictive test for the disease: Its computer tool that helps predict Alzheimer’s disease three to six years before the first symptoms appear – opening up opportunity for docs to begin early […]